Hoshi Iryo-Sanki (7634) Q2 2026 earnings summary

Executive summary

• Revenue for the six months ended September 30, 2025, was ¥7,372 million, up 1.2% year-over-year, with operating profit at ¥863 million, down 1.9%, and net profit attributable to shareholders at ¥622 million, nearly flat year-over-year.

• The company prioritized stable supply of products and services, safety, and social responsibility in the medical, nursing, and welfare sectors amid a gradually recovering domestic economy and ongoing global uncertainties.

Financial highlights

• Operating profit margin declined slightly as operating profit fell 1.9% year-over-year despite a 1.2% increase in revenue.

• Comprehensive income rose 8.6% year-over-year to ¥860 million, reflecting gains in securities valuation.

• Total assets increased to ¥25,389 million, up ¥799 million from the previous fiscal year-end.

• Equity ratio improved to 75.5% from 74.9% at the previous year-end.

• Cash and cash equivalents at period-end were ¥5,693 million, down ¥232 million from the start of the period.

Outlook and guidance

• Full-year revenue is forecast at ¥15,260 million (up 1.0% year-over-year), with operating profit of ¥2,070 million (up 3.7%) and net profit attributable to shareholders of ¥1,476 million (up 0.9%).

• No changes have been made to the previously announced full-year forecast.

• Annual dividend forecast was revised upward to ¥90 per share from ¥70 per share.